Clinical trials: Respiratory Syncytial Viruses
Respiratory Syncytial Virus (RSV)
A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
The purpose of this study is to elucidate the molecular mechanism by which novel adjuvants enhance the immunogenicity of Respiratory Syncytial Virus (RSV) vaccines by regulating antigen-specific B cell affinity maturation and T…
- Trial name
- NCT07618325
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
RSV Infection
Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children
Study D5290C00008 is a Phase 2, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetic(s) (PK), occurrence of antidrug antibody (ADA), and efficacy of nirsevimab in immunocompromised…
- Trial name
- MUSIC (NCT04484935)
- Testing
- Nirsevimab
- Where
- 28 sites in United States, Belgium and 6 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a…
- Trial name
- RSV OA=ADJ-023 (NCT05921903)
- Testing
- RSVPreF3 OA Investigational Vaccine
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset
This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS).
- Trial name
- BORLAND (NCT07235397)
- Testing
- ABRYSVO
- Volunteers
- 1 people
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infections, Parainfluenza Infections
Study to Evaluate MEDI-534 in Healthy Adults
The primary objective of this study is to describe the safety and tolerability of a single dose of MEDI-534 when administered to healthy adult volunteers.
- Trial name
- NCT00111878
- Testing
- MEDI-534
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Respiratory Syncytial Viruses, Respiratory Tract Infections
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers
The purpose of this study is to assess the safety and tolerability of intramuscular prime-boost regimens of Ad26.RSV.FA2 given either once or twice followed by Ad35.RSV.FA2 (human adenovirus-vectored vaccine candidate) in healthy…
- Trial name
- NCT02561871
- Testing
- Ad26.RSV.FA2, Ad35.RSV.FA2
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Respiratory Syncytial Virus Infection, Premature Birth
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial…
- Conditions
- Respiratory Syncytial Virus Infection, Premature Birth, Bronchopulmonary Dysplasia, Congenital Heart Disease
- Trial name
- NCT01006629
- Testing
- palivizumab
- Where
- 19 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Abbott
Respiratory Syncytial Virus Infections
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in…
- Trial name
- NCT04732871
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 46 sites in United States, Finland and 3 more
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
MVA-BN-RSV Vaccine Trial
Phase 3 randomized, double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults >=60 years of age
- Trial name
- NCT05238025
- Testing
- MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
- Where
- 120 sites in United States, Germany
- Volunteers
- 20,419 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Respiratory Syncytial Virus, Human Metapneumovirus
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
Study VCA25397 is a Phase 2b, observer-blind, randomized, placebo-controlled, parallel, case-driven proof of concept study that will enroll approximately 8000 adults aged 60 years and older to assess the clinical efficacy…
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus, Healthy Volunteers
- Trial name
- NCT07810010
- Testing
- Bivalent RSV+HMPV protein vaccine
- Where
- 21 sites in Australia, United Kingdom
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
RESPIRATORY SYNCYTIAL VIRUS (RSV)
A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age
The purpose of this study is to learn about the safety and immune activity of the vaccine (called RSVpreF) in children 2 to <18 years of age.
- Trial name
- PICASSO (NCT05900154)
- Testing
- RSVpreF 120 µg, RSVpreF 60 µg
- Where
- 17 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infections
Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult hematopoietic stem cell transplant (HSCT) recipients…
- Trial name
- FREESIA (NCT04056611)
- Testing
- JNJ-53718678 250 mg, JNJ-53718678 125 mg
- Where
- 69 sites in United States, Argentina and 15 more
- Volunteers
- 3 people
- Sponsor
- Janssen Sciences Ireland UC
Respiratory Syncytial Virus
BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
The primary objectives of the study are: To estimate the effectiveness of nirsevimab against polymerase chain reaction (PCR)-confirmed RSV (1) lower respiratory tract (LRTD) and (2) related medical encounters.
- Trial name
- BEAR (NCT06325332)
- Testing
- Nirsevimab
- Where
- United States
- Volunteers
- 49,680 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infections
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above
The study will evaluate the safety, tolerability, and immunogenicity of 3 dose levels of IN006 in healthy adults aged 18 Years and Above; of a revaccination of IN006 given approximately 12 months after the initial vaccination in…
- Trial name
- NCT06645665
- Testing
- Bivalent RSV Vaccine (IN006)
- Where
- 2 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
Respiratory Syncytial Virus Infection
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower…
- Trial name
- NCT02254421
- Testing
- Presatovir
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Respiratory Syncytial Virus (RSV)
Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden
Primary Objective: -Estimate the hospital-associated healthcare resource use (HCRU), and associated costs, of RSV infection in children in comparison to the non-RSV control cohort (general population) and patients with rhinovirus…
- Trial name
- NCT05622331
- Volunteers
- 1,100,000 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Drug Safety, Respiratory Syncytial Virus Infections
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
The purpose of this study is to determine the range of single inhaled doses of a new dry powder product, MDT-637, that are safe and well-tolerated.
- Trial name
- NCT01355016
- Testing
- MDT-637
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MicroDose Therapeutx, Inc
RSV Immunization, Healthy Volunteer
Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life
The purpose of this study was to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection…
- Trial name
- NCT05437510
- Testing
- Nirsevimab
- Where
- 240 sites in France, Germany and 1 more
- Volunteers
- 8,057 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
RSV Infection
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
This was a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who were at high risk for complications…
- Trial name
- RSVHR (NCT05568706)
- Testing
- EDP-938
- Where
- 84 sites in United States, Argentina and 10 more
- Volunteers
- 187 people
- Sponsor
- Enanta Pharmaceuticals, Inc
RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Viral Inhibition in Children for Treatment of RSV
VICTOR is a randomized, double-blind, placebo-controlled, multicenter, 2-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effect of single and multiple dosing of AK0529 in infants…
- Trial name
- VICTOR (NCT02654171)
- Testing
- AK0529
- Where
- 28 sites in Australia, Hong Kong and 6 more
- Volunteers
- 72 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.